Requirements for complement and antibody in neutrophil-mediated killing of serotype IV and V group B streptococci were investigated. Neutrophils from adults were tested in an opsonophagocytic assay with sera from healthy adults, healthy newborns, and hypogammaglobulinemic, agammaglobulinemic, and C4-deficient patients. For all serum sources, the bactericidal index for both serotypes exceeded 84% after 40 IV and V (10, 20, 21) . Like those of other GBS serotypes, type IV and V capsular polysaccharides consist of repeating polymers containing galactose, glucose, N-acetylglucosamine, and sialic acid (20, 21) . Electron microscopy of type IV strains demonstrates a thin layer of scantily and irregularly distributed material on the surface of the organism, whereas the type V capsule is regular in distribution and more dense (13, 17) .
Requirements for complement and antibody in neutrophil-mediated killing of serotype IV and V group B streptococci were investigated. Neutrophils from adults were tested in an opsonophagocytic assay with sera from healthy adults, healthy newborns, and hypogammaglobulinemic, agammaglobulinemic, and C4-deficient patients. For all serum sources, the bactericidal index for both serotypes exceeded 84% after 40 min of incubation. Heat inactivation of sera ablated killing. Blockade of neutrophil receptor FcIII effected a maximum of 16% inhibition of opsonophagocytosis, and FcII receptor blockade demonstrated negligible inhibition. When neutrophil complement receptor 1 or 3 blockade was employed, the maximum inhibition detected was 26%. Simultaneous blockade of complement receptors 1 and 3 effected maximum inhibition levels of 25 and 65% for serotypes IV and V, respectively. Blockade of complement receptor 3 and neutrophil receptor FcIII inhibited opsonophagocytosis by 56% for both serotypes. When serum complement concentrations were restricted, neutrophil-mediated killing diminished but was restored by the addition of hyperimmune rabbit antiserum.
These findings suggest that complement and antibody are major participants in the opsonophagocytosis of serotypes IV and V group B streptococci. A low prevalence of carriage or mediation of efficient phagocytosis by interactions of neutrophil complement and Fc receptors may contribute to the rarity of human infections caused by these two serotypes.
Group B streptococci (GBS) continue to be a major cause of serious infection in neonates and immunocompromised adults. The type-specific capsular polysaccharide and its sialic acid component have been considered important virulence factors among GBS serotypes. The capsular polysaccharides Ia, Ib, II, and III and a protein antigen, c, have been used to classify GBS strains into distinct serotypes. Approximately 5 to 10% of isolates from human sources, however, are considered nontypeable (14, 15) . Recently, some isolates previously described as nontypeable were characterized as belonging to antigenically distinct serotypes IV and V (10, 20, 21) . Like those of other GBS serotypes, type IV and V capsular polysaccharides consist of repeating polymers containing galactose, glucose, N-acetylglucosamine, and sialic acid (20, 21) . Electron microscopy of type IV strains demonstrates a thin layer of scantily and irregularly distributed material on the surface of the organism, whereas the type V capsule is regular in distribution and more dense (13, 17) .
Though isolated infrequently, type IV and V GBS do cause invasive human infection and have been identified among isolates from at least 15 countries (11) . Knowledge of host defense mechanisms for response to disease due to these serotypes is limited, however. The present study was designed to investigate host factors possibly defining susceptibility to type IV and V GBS. Efficient phagocytosis of other GBS serotypes by neutrophils (polymorphonuclear leukocytes [PMNL] ) requires opsonization with complement and may or may not depend on the presence of antibody to the capsular polysaccharide (4) (5) (6) . We examined complement and antibody participation and requirements for complement and Fc receptors in PMNL-mediated killing of these new serotypes.
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MATERIALS AND METHODS
Collection and preparation of sera. Sera were separated from whole blood obtained by venipuncture and processed to preserve endogenous complement activity (18 (3) . The concentrations also were confirmed as optimal functionally by performing dose-response experiments at concentrations ranging from 0.6 to 20 p,g/ml in the opsonophagocytic assay. When MAb combinations were tested, the final concentration of each was equal to its concentration when employed independently.
OP assay. The opsonophagocytosis (OP) assay described previously (6) Antibody determination. Serum antibody to serotype IV GBS was determined by using an IgG-specific enzymelinked immunosorbent assay (ELISA) based on the method of Eisenstein et al. (7) . Purified type IV polysaccharide (provided by Michael Wessels, Boston, Mass.) was bound to polystyrene Immulon 1 U-bottom microtiter plates (Dynatech Laboratories, Inc., Alexandria, Va.) with poly-L-lysine (Mr, 540,000) as described by Gray (9) . A whole-cell ELISA was carried out to determine antibody titers to type V GBS. Log-phase bacteria were resuspended in carbonate-bicarbonate coating buffer (pH 9.6) for binding to wells of microtiter plates. Serum dilutions were prepared in PBSTween 20. Alkaline phosphatase-conjugated goat anti-human IgG or sheep anti-rabbit IgG (Sigma) was employed to bind human or hyperimmune rabbit serum (IRS), respectively. p-Nitrophenyl phosphate disodium substrate tablets (Sigma) were employed for color development, and the optical density at 405 nm was read on an enzyme immunoassay reader (model MR 5000; Dynatech Laboratories, Inc., Chantilly, Va.).
Statistics. Data were analyzed by the Student unpaired t test (two tailed) (8) .
RESULTS
Preliminary experiments were performed to determine the kinetics of opsonophagocytosis of clinical isolates of serotype IV and V GBS by PMNL from adults. Aliquots were plated initially and after 10, 20, 40, and 80 min of incubation. At the 10-and 20-min intervals, the NHS pool with added heat-inactivated IRS reduced the initial inoculum to a greater extent than did other serum sources ( Fig. 1 and 2) . At 40 min, the NHS pool and HGS also promoted 275% reduction in CFU per milliliter for both serotypes. The addition of heat-inactivated IRS to the NHS pool further augmented killing of type IV GBS. After 80 min, HGS, the NHS pool, and the NHS pool plus heat-inactivated IRS promoted reduction of CFU approaching or exceeding 1 log1o unit (90%) for both serotypes. With heat-inactivation, the NHS pool and IRS effected no reduction in inoculum, and reaction mixtures lacking serum or PMNL permitted bacterial growth. The 40-min incubation interval was chosen to examine the participation of complement and antibody in PMNL-mediated killing.
Effect of antibody on OP. The reciprocal serum dilutions providing an optical density at 405 nm of 20.2 for the serum sources employed are shown in Table 1 . As expected, IgG antibody with specificity for type IV or V GBS was not detectable in AGS. In contrast, antibodies were detectable to a dilution of 105 in IRS, whereas intermediate levels of naturally acquired antibodies were found in the other human sera. The effect of antibody on the OP of type IV and V GBS then was determined ( Table 2 ). The two adult sera (NHS1 and NHS2) and the NHS pool reduced the initial GBS inoculum by at least 84% + 11%. Healthy term neonate sera containing total IgG and GBS antibody titers comparable to those in adult sera had mean bactericidal indices (BIs) of 89% + 13% for type IV GBS and 97% + 2% for type V GBS. HGS and AGS, the latter with essentially undetectable IgG (10 mg/dl), promoted BIs of 88% + 6% and 91% ± 6%, respectively, for type IV GBS and 86% ± 6% and 84% ± 5%, respectively, for type V GBS. Reaction mixtures lacking serum or PMNL permitted bacterial growth.
To better assess the role of antibody, diminishing concentrations of complement associated with various dilutions of IRS were employed in the OP assay. The NHS pool was employed at 10, 5, and 1% as a serum source alone or with heat-inactivated IRS in the reaction mixture (Fig. 3) . With 10% NHS pool, IRS minimally augmented the BI. When 5% complement was employed, the effect was more pronounced; the mean BIs increased from 67% to 96% (type IV) and from 51% to 92% (type V), respectively. Results with 1% NHS pool were the most striking; IRS increased the BIs from 0% to 92% and 89% for type IV and V GBS, respectively. Heat-inactivated IRS employed alone as a serum source did not kill either serotype. The optimal dilution of IRS was 1:10 or 1:100, depending on the complement concentration and GBS serotype. These results suggest that antibody has an important role in PMNL-mediated killing of type IV and V GBS when complement concentrations are diminished. However, when serum complement is present in sufficient concentrations, killing can be mediated independently of antibody.
Requirement for complement in OP. To determine whether there was an absolute requirement of complement for PMNL-mediated killing of type IV or V GBS, NHS2 and HGS were subjected to heating at 56°C for 30 min. This ablated bacterial killing, suggesting an absolute requirement of complement for opsonization and phagocytosis to occur. To assess the complement pathway used, C4D serum was employed. This serum promoted BIs of 91% ± 1% and 87% 
FIG. 2. Kinetics of OP of type V GBS by the NHS pool (0), the NHS pool with heat-inactivated IRS (*), and HGS (+). Controls included heat-inactivated NHS pool (A), heat-inactivated IRS (V), no PMNL (*), and no serum (v).
Results represent the means of three determinations for each interval. Standard deviations were c70 CFU/ml at 0, 10, and 20 min of incubation. At 40 and 80 min, standard deviations were .250 CFU/ml. + 0% for type IV and V GBS, respectively (Table 3) . These results indicate that PMNL-mediated killing of types IV and V GBS may proceed via the alternative complement pathway when the classical complement pathway is not available.
Role of complement and Fc receptors in OP. The effects of PMNL complement and Fc receptor blockade by MAb were tested in the OP assay. Initial experiments determined dose-response relationships of inhibition of OP for each MAb. To reveal optimum functional activity, MAbs in concentrations ranging from 0.6 to 20 ,ug/ml in the reaction (13) 97 (2) No serum 0 0 NoPMNL 0 0 mixture were incubated with neutrophils from adults and bacteria opsonized with NHS1. The optimal concentrations for each MAb tested ranged from 2.5 to 10 ,ug/ml. These results correlated with saturating concentrations demonstrated by immunofluorescence flow cytometry, and MAbs were employed as shown in Table 4 . Blockade of PMNL CR1 by MAb CD35 effected 3% + 2% and 13% + 14% inhibition of OP for serotypes IV and V GBS, respectively (Table 4) . CR3 blockade by Leu 15, M1/70, Mol, or OKM1 effected a maximum of 11% + 9% and 26% + 7% inhibition of intracellular killing for type IV and V GBS, respectively. MAb to PMNL FcRIII, 3G8, demonstrated a mean inhibition of 7% ± 6% and 16% ± 14%, respectively, for serotypes IV and V. The F(ab')2 fragment of 3G8 inhibited a mean of 3% + 4% and 5% ± 5%, respectively. MAb to PMNL FcRII, IV.3, mediated negligible inhibition for both serotypes. Isotypic control MAbs did not effect OP activity. These results suggest that blockade of a single PMNL receptor is not sufficient to substantially impede PMNL-mediated killing of type IV and V GBS. In addition to a low prevalence of carriage, efficient phagocytosis, mediated by interactions between neutrophil complement and Fc receptors, may account for the rarity of infections caused by these serotypes in neonates.
Since all of the MAbs demonstrated minimal inhibition individually (<26%) for type IV and V GBS, a representative (10) 5 (5) 1 (1) 3G8 (5) 7 (6) (10) 56 (17) 56 (11) MsIgGC (8) 4 (4) 5 (5) a The type IV initial BI was 97% (3%), and the type V initial BI was 96% (3%). 46% ± 25% for CD35 plus M1/70 combinations for types IV and V, respectively. PMNL CR3 plus FcRIII blockade was tested in combination using Leu 15 and 3G8. Levels of inhibition of killing were 56% ± 17% and 56% ± 11%, respectively, for type IV and V GBS and were significantly greater than those detected when these MAbs were employed alone (P c 0.03). On the basis of these results, multiple deficiencies in complement protein production or PMNL receptor upregulation could explain enhanced virulence of GBS types IV and V in some newborns.
DISCUSSION
Knowledge of host factors explaining the susceptibility of neonates to type IV and V GBS infections is limited. Our experiments evaluated the role of complement and antibody in PMNL-mediated killing of these recently defined serotypes. The objective was to define the relative contributions and interactions of these opsonins. A number of conclusions may be drawn from our results. First, complement appears to have a prominent role in the OP of type IV and V GBS. All sera with intact complement, including HGS and AGS, promoted significant PMNL-mediated killing after 40 min of incubation. Anitibody titers in AGS were undetectable by ELISA when compared to the other serum sources, but OP activities were the same among the various sera. Heat inactivation of sera, regardless of source, ablated killing.
Thus, complement is required for OP and appears to be capable of acting independently of antibody in promoting neutrophil-mediated killing of type IV and V GBS.
The role of antibody appears to be of some significance. Kinetically, heat-inactivated IRS increased OP activity promoted by the NHS pool at a rate faster than that promoted by the NHS pool alone or by HGS. Antibody appears to be even more important, however, when complement is limited. Limiting the NHS pool to 5 or 1% concentration resulted in poor or no OP activity. Killing was restored by the addition of heat-inactivated, type-specific IRS. This suggests that antibody, presumably in very high titers, efficiently promotes killing of type IV and V GBS when complement is available in very low concentrations. We also observed that type IV and V GBS may be opsonized efficiently via the alternative complement pathway. Serum deficient in C4 supported efficient neutrophilmediated killing of both organisms. This finding is consistent with but does not prove the importance of the alternative complement pathway for opsonization of type IV and V GBS in the setting of specific antibody deficiency.
Finally, type IV and V GBS have opsonic requirements that are distinct from those of other well-defined GBS serotypes. Antibody and complement both play integral roles in OP of type III GBS (6), the most common serotype causing invasive GBS disease in newborns. Type III strains require antibody with specificity for capsular polysaccharide for optimal opsonization. In contrast, type Ia GBS strains may employ the classical complement pathway for PMNLmediated killing in an antibody-independent fashion (4). T'ype IV and V GBS appear similar to type Ia GBS in that complement alone may promote killing. However, type IV and V GBS are similar to both of these major serotypes in that heat-inactivated serum does not support opsonization.
In addition, the extent of inhibition of BI seen with monoclonal antibodies alone or in combination is lower for type IV and V GBS than that observed for serotype Ia or III GBS (18) . In particular, only the combination of 3G8 and Leu 15 promoted substantial inhibition for type IV GBS. However, examination of additional clinical strains of types IV and V will be necessary to confirm these observations. Since all of the sera used for these experiments promoted efficient PMNL-mediated killing of type IV and V GBS, these organisms presumably are removed easily from the bloodstream, even in neonates. Complement appears to have an essential role in opsonization and phagocytosis of these two serotypes. Interactive neutrophil complement and Fc receptor mediation may contribute to the rarity of type IV and V GBS infections in neonates. Conversely, low prevalence of carriage may account for the infrequent occurrence of neonatal disease due to these serotypes. Since the expression of neutrophil receptors in immature hosts may be diminished relative to that in adults (19) , enhanced susceptibility of some hosts to type IV or V GBS might best be explained by deficiencies in complement function or decreased receptor interactions.
